Flerie made decisions about capital reduction and bonus issue
The extraordinary general meeting decided on the withdrawal of common shares and a bonus issue to neutralize the capital reduction.
See the latest news and media coverage for Flerie. We track all announcements, press releases, and industry mentions in real time, all in one place.
Active long-term life science investor
flerie.comLast updated
In short: Flerie completed a merger with Lipum, reported a net asset value of SEK 3,466 million for May 2026, and advanced several clinical portfolio assets.
The extraordinary general meeting decided on the withdrawal of common shares and a bonus issue to neutralize the capital reduction.
Xspray Pharma analyzes the FDA response and intends to address the comments. FDA requires dose correspondence, manufacturing data, and GMP observations.
The phase I/IIa study met safety objectives in venous leg ulcer patients, supporting further development.
The change is due to a bonus issue of 11,888,785 new ordinary shares resolved at the annual general meeting.
Follow real-time insider transactions on Flerie Invest AB. Filter by importance or type of operation and analyze the history on Zonebourse.
Flerie AB: Prokarium, a portfolio company of Flerie, presents positive interim clinical data in the treatment of bladder cancer The profile...
Flerie AB: Finalization of the incorporation of reserves into capital Issuance of 11,888,785 new shares; the total number of shares now amounts to...
Thomas Eldered, main shareholder of the investment company Flerie, has undertaken to return all the securities that will be allocated to him during the capital increase...
Track Flerie and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Flerie and other trending companies.